EXTON, Pa., July 1 In conjunction with yesterday's FDA approval of AMAG Pharmaceuticals' Feraheme (ferumoxytol), BioTrends Research Group, Inc. is pleased to announce LaunchTrends(TM): Feraheme, a syndicated report series that will track the trial, adoption and usage of Feraheme. Feraheme is a new IV Iron product approved to treat iron deficiency anemia in patients with Chronic Kidney Disease, both on and not on dialysis. Surveys will be fielded at one month, three months, and six months post launch. Each report consists of findings from a quantitative survey with 50 Nephrologists and qualitative interviews with a subset of the survey respondents.
BioTrends has been following Feraheme in its TreatmentTrends(R): US Nephrology reports since the end of 2006. According to the most recent TreatmentTrends(R) survey, interest in the product is high, particularly in the CKD-ND setting, although Nephrologists predict uptake across all patient types.
LaunchTrends(TM) measure launch effectiveness of new products from FDA approval through six months post launch. The first wave of the LaunchTrends(TM): Feraheme report series will be fielded in mid-August, measuring uptake at one month. Topline findings will be available shortly thereafter and the full report will follow in mid-September.
About BioTrends Research Group, Inc.
BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact us at (610) 363-3872 or visit us at www.bio-trends.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
SOURCE BioTrends Research Group, Inc.